Treatment of severe steroid refractory ulcerative colitis

World Journal of Gastroenterology

Volumn 14, Issue 36, 2008, Pages 5508-5511

  Van Assche, Gert ^a   Vermeire, Séverine ^a   Rutgeerts, Paul ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Azathioprine; Corticosteroids; Cyclosporine; Immunosuppressants; Infliximab; Steroids; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; INFLIXIMAB; MERCAPTOPURINE; METHYLPREDNISOLONE; METRONIDAZOLE; MONOCLONAL ANTIBODY; PREDNISOLONE; STEROID; TACROLIMUS; TUMOR NECROSIS FACTOR; ANTIINFLAMMATORY AGENT; GASTROINTESTINAL AGENT; IMMUNOSUPPRESSIVE AGENT;

ABDOMINAL RADIOGRAPHY; ANAPHYLAXIS; ARTICLE; BLOOD ANALYSIS; COLON RESECTION; COLONOSCOPY; CONTINUOUS INFUSION; CONVULSION; DISEASE SEVERITY; DRUG EFFICACY; GINGIVA HYPERPLASIA; HUMAN; HYPERTENSION; HYPERTRICHOSIS; MEDICAL DECISION MAKING; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; PERITONITIS; PNEUMOCYSTIS PNEUMONIA; SIGMOIDOSCOPY; TREATMENT FAILURE; TREATMENT RESPONSE; TREMOR; ULCERATIVE COLITIS; DRUG ADMINISTRATION ROUTE; DRUG RESISTANCE; HOSPITALIZATION; PATHOLOGY; PRACTICE GUIDELINE; REVIEW;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COLECTOMY; COLITIS, ULCERATIVE; COLONOSCOPY; CYCLOSPORINE; DRUG ADMINISTRATION ROUTES; DRUG RESISTANCE; GASTROINTESTINAL AGENTS; HOSPITALIZATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PRACTICE GUIDELINES AS TOPIC; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE;

EID: 58149186111     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.5508     Document Type: Article

References (20)

1. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Final report on a therapeutic trial. Br Med J 1955; 2: 104-108
2. Baron JH, Connell AM, Kanaghinis TG, Lennard-Jones JE, Jones AF. Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone. Br Med J 1962; 2: 441-443
3. Truelove SC, Willoughby CP, Lee EG, Kettlewell MG. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet 1978; 2: 1086-1088
4. Travis SP, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MG, Jewell DP. Predicting outcome in severe ulcerative colitis. Gut 1996; 38: 905-910
5. Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. Gut 1963; 4: 299-315
6. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F, Hanauer S. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841-1845
7. D'Haens G, Lemmens L, Geboes K, Vandeputte L, Van Acker F, Mortelmans L, Peeters M, Vermeire S, Penninckx F, Nevens F, Hiele M, Rutgeerts P. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001; 120: 1323-1329
8. Van Assche G, D'Haens G, Noman M, Vermeire S, Hiele M, Asnong K, Arts J, D'Hoore A, Penninckx F, Rutgeerts P. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003; 125: 1025-1031
9. Arts J, D'Haens G, Zeegers M, Van Assche G, Hiele M, D'Hoore A, Penninckx F, Vermeire S, Rutgeerts P. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 2004; 10: 73-78
10. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999; 94: 1587-1592
11. Moskovitz DN, Van Assche G, Maenhout B, Arts J, Ferrante M, Vermeire S, Rutgeerts P. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol 2006; 4: 760-765
12. Campbell S, Travis S, Jewell D. Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur J Gastroenterol Hepatol 2005; 17: 79-84
13. de Saussure P, Soravia C, Morel P, Hadengue A. Lowdose oral microemulsion ciclosporin for severe, refractory ulcerative colitis. Aliment Pharmacol Ther 2005; 22: 203-208
14. Fellermann K, Tanko Z, Herrlinger KR, Witthoeft T, Homann N, Bruening A, Ludwig D, Stange EF. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis 2002; 8: 317-324
15. Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease - a long-term follow-up. Am J Gastroenterol 2006; 101: 1048-1056
16. Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlén P, Grännö C, Vilien M, Ström M, Danielsson A, Verbaan H, Hellström PM, Magnuson A, Curman B. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128: 1805-1811
17. Medlinechey WY. Infliximab for patients with refractory ulcerative colitis. Inflamm Bowel Dis 2001; 7 Suppl 1: S30-S33
18. Regueiro M, Curtis J, Plevy S. Infliximab for hospitalized patients with severe ulcerative colitis. J Clin Gastroenterol 2006; 40: 476-481
19. Maser E, Deconda D, Lichtiger S, Present D, Kornbluth A. Cyclosporine (CsA) and infliximab (Infl) as acute salvage therapies for each other in severe steroid refractory ulcerative colitis (UC). Gastroenterology 2007; 132: A180
20. Selvasekar CR, Cima RR, Larson DW, Dozois EJ, Harrington JR, Harmsen WS, Loftus EV Jr, Sandborn WJ, Wolff BG, Pemberton JH. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg 2007; 204: 956-962; discussion 962-963